use of tumor markers in testicular, prostate, colorectal, breast, and ...

References 69
268. Filella X, Molina R, Pique JM, Garcia-Valdecasas JC, Grau JJ,
Novell F, et al. Use of CA 19-9 in the early detection of recurrences
in colorectal cancer: comparison with CEA. Tumour Biol
1994;15:1–6.
269. Nilsson O, Johansson C, Glimelius B, Persson B, Norgaard-
Pedersen B, Andren-Sandberg A, Lindholm L. Sensitivity and
specificity of CA242 in gastro-intestinal cancer. A comparison
with CEA, CA50 and CA 19-9. Br J Cancer 1992;65:215–221.
270. Carpelan-Holmstrom M, Haglund C, Lundin J, Alfthan H,
Stenman UH, Roberts PJ. Independent prognostic value of preoperative
serum markers CA 242, specific tissue polypeptide
antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic
antigen or tissue polypeptide antigen in colorectal
cancer. Br J Cancer 1996;74:925–929.
271. Carpelan-Holmstrom M, Haglund C, Lundin J, Jarvinen H,
Roberts P. Pre-operative serum levels of CA 242 and CEA predict
outcome in colorectal cancer. Eur J Cancer 1996;
32A:1156–1161.
272. Holten-Andersen MN, Christensen IJ, Nielsen HJ, Stephens RW,
Jensen V, Nielsen OH, et al. Total levels of tissue inhibitor of
metalloproteinases 1 in plasma yield high diagnostic sensitivity
and specificity in patients with colon cancer. Clin Cancer Res
2002;8:156–164.
273. Holten-Andersen MN, Fenger C, Nielsen HJ, Rasmussen AS,
Christensen IJ, Brunner N, Kronborg O. Plasma TIMP-1 in
patients with colorectal adenomas: a prospective study. Eur J
Cancer 2004;40:2159–2164.
274. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G,
Christensen IJ, Stetler-Stevenson W, Brunner N. High preoperative
plasma tissue inhibitor of metalloproteinase-1 levels are
associated with short survival of patients with colorectal cancer.
Clin Cancer Res 2000;6:4292–4299.
275. Holten-Andersen M, Christensen IJ, Nilbert M, Bendahl PO,
Nielsen HJ, Brunner N, Fernebro E. Association between preoperative
plasma levels of tissue inhibitor of metalloproteinases
1 and rectal cancer patient survival. a validation study. Eur J
Cancer 2004;40:64–72.
276. Johnston PG, Benson AB, III, Catalano P, Rao MS, O’Dwyer
PJ, Allegra CJ. Thymidylate synthase protein expression in primary
colorectal cancer: lack of correlation with outcome and
response to fluorouracil in metastatic disease sites. J Clin Oncol
2003;21:815–819.
277. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG,
Magnusson I, et al. Thymidylate synthase expression in colorectal
cancer: a prognostic and predictive marker of benefit from
adjuvant fluorouracil-based chemotherapy. J Clin Oncol
2002;20:1721–1728.
278. Allegra C. Thymidylate synthase levels: prognostic, predictive,
or both? J Clin Oncol 2002;20:1711–1713.
279. Popat S, Matakidou A, Houlston RS. Thymidylate synthase
expression and prognosis in colorectal cancer: a systematic
review and meta-analysis. J Clin Oncol 2004;22:529–536.
280. Aschele C, Lonardi S, Monfardini S. Thymidylate Synthase
expression as a predictor of clinical response to fluoropyrimidine-based
chemotherapy in advanced colorectal cancer. Cancer
Treat Rev 2002;28:27–47.
281. Samowitz WS, Curtin K, Ma KN, Schaffer D, Coleman LW,
Leppert M, Slattery ML. Microsatellite instability in sporadic colon
cancer is associated with an improved prognosis at the population
level. Cancer Epidemiol Biomarkers Prev 2001;10:917–923.
282. Kohonen-Corish MR, Daniel JJ, Chan C, Lin BP, Kwun SY,
Dent OF, et al. Low microsatellite instability is associated with
poor prognosis in stage C colon cancer. J Clin Oncol
2005;23:2318–2324.
283. Popat S, Hubner R, Houlston RS. Systematic review of
microsatellite instability and colorectal cancer prognosis. J Clin
Oncol 2005;23:609–618.
284. Elsaleh H, Powell B, McCaul K, Grieu F, Grant R, Joseph D,
Iacopetta B. P53 alteration and microsatellite instability have
predictive value for survival benefit from chemotherapy in stage
III colorectal carcinoma. Clin Cancer Res 2001;7:1343–1349.
285. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ,
Goldberg RM, et al. Tumor microsatellite-instability status as a
predictor of benefit from fluorouracil-based adjuvant
chemotherapy for colon cancer. N Engl J Med 2003;
349:247–257.
286. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele
G, Jr., et al. The DCC protein and prognosis in colorectal cancer.
N Engl J Med 1996;335:1727–1732.
287. Aschele C, Debernardis D, Lonardi S, Bandelloni R, Casazza
S, Monfardini S, Gallo L. Deleted in colon cancer protein
expression in colorectal cancer metastases: a major predictor of
survival in patients with unresectable metastatic disease receiving
palliative fluorouracil-based chemotherapy. J Clin Oncol
2004;22:3758–3765.
288. Popat S, Houlston RS. A systematic review and meta-analysis
of the relationship between chromosome 18q genotype, DCC
status and colorectal cancer prognosis. Eur J Cancer
2005;41:2060–2070.
289. Skelly MM, Troy A, Duffy MJ, Mulcahy HE, Duggan C, Connell
TG, et al. Urokinase-type plasminogen activator in colorectal
cancer: relationship with clinicopathological features and patient
outcome. Clin Cancer Res 1997;3:1837–1840.
290. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA,
O’Donoghue DP, Sheahan K. Urokinase-type plasminogen activator
and outcome in Dukes’ B colorectal cancer. Lancet
1994;344:583–584.
291. Yang JL, Seetoo D, Wang Y, Ranson M, Berney CR, Ham JM,
et al. Urokinase-type plasminogen activator and its receptor in
colorectal cancer: independent prognostic factors of metastasis
and cancer-specific survival and potential therapeutic targets. Int
J Cancer 2000;89:431–439.
292. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR,
Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal
cancer: the ‘RASCAL II’study. Br J Cancer 2001; 85:692–696.
293. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes
in colorectal cancer: a systematic review. Br J Cancer
2005;92:434–444.
294. Lievre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et
al. KRAS mutations as an independent prognostic factor in
patients with advanced colorectal cancer treated with cetuximab.
J Clin Oncol 2008;26:374–379.
295. De Roock W, Piessevaux H, De Schutter J, Janssens M, De
Hertogh G, Personeni N, et al. KRAS wild-type state predicts
survival and is associated to early radiological response in
metastatic colorectal cancer treated with cetuximab. Ann Oncol
2008;19:508–515.
296. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et
al. KRAS mutation status is predictive of response to cetuximab
therapy in colorectal cancer. Cancer Res 2006;66:3992–3995.
297. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S,
Freeman DJ, et al. Wild-type KRAS is required for panitumumab
efficacy in patients with metastatic colorectal cancer. J Clin
Oncol 2008;26:1626–1634.